Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Chemoattractant-mediated leukocyte trafficking enables HIV dissemination from the genital mucosa
Maud Deruaz, Thomas T. Murooka, Sophina Ji, Marc A. Gavin, Vladimir D. Vrbanac, Judy Lieberman, Andrew M. Tager, Thorsten R. Mempel, Andrew D. Luster
Maud Deruaz, Thomas T. Murooka, Sophina Ji, Marc A. Gavin, Vladimir D. Vrbanac, Judy Lieberman, Andrew M. Tager, Thorsten R. Mempel, Andrew D. Luster
View: Text | PDF
Research Article AIDS/HIV Immunology

Chemoattractant-mediated leukocyte trafficking enables HIV dissemination from the genital mucosa

  • Text
  • PDF
Abstract

HIV vaginal transmission accounts for the majority of newly acquired heterosexual infections. However, the mechanism by which HIV spreads from the initial site of viral entry at the mucosal surface of the female genital tract to establish a systemic infection of lymphoid and peripheral tissues is not known. Once the virus exits the mucosa it rapidly spreads to all tissues, leading to CD4+ T cell depletion and the establishment of a viral reservoir that cannot be eliminated with current treatments. Understanding the molecular and cellular requirements for viral dissemination from the genital tract is therefore of great importance, as it could reveal new strategies to lengthen the window of opportunity to target the virus at its entry site in the mucosa where it is the most vulnerable and thus prevent systemic infection. Using HIV vaginal infection of humanized mice as a model of heterosexual transmission, we demonstrate that blocking the ability of leukocytes to respond to chemoattractants prevented HIV from leaving the female genital tract. Furthermore, blocking lymphocyte egress from lymph nodes prevented viremia and infection of the gut. Leukocyte trafficking therefore plays a major role in viral dissemination, and targeting the chemoattractant molecules involved can prevent the establishment of a systemic infection.

Authors

Maud Deruaz, Thomas T. Murooka, Sophina Ji, Marc A. Gavin, Vladimir D. Vrbanac, Judy Lieberman, Andrew M. Tager, Thorsten R. Mempel, Andrew D. Luster

×

Figure 3

FTY720 treatment interferes with HIV spread to the lymph nodes (LNs) and prevents infection from leaving LNs.

Options: View larger image (or click on image) Download as PowerPoint
FTY720 treatment interferes with HIV spread to the lymph nodes (LNs) and...
(A) Scheme of the experimental treatment. BLT-NSG mice received PBS (control) or FTY720 daily i.p. starting 4 days prior to or on the day of intravaginal (IVAG) infection, and received PBS or FTY720 daily IVAG starting 3 hours postinfection. CCR7 mAb (αCCR7) i.p. and IVAG treatments were performed as described in Figure 2. Presence of HIV RNA in plasma (B) and tissues (C) at 14 days postinfection (dpi) of control (open circles, n = 8), FTY720-treated (FTY, black circles, n = 12), and FTY720+CCR7 mAb–treated (FTY+R7, gray circles, n = 4) mice. Each circle in B–F represents 1 mouse. The FTY720-treated mouse with borderline viremia is highlighted in red. Dotted line: limit of sensitivity of the assay; gray box: ± 2 SD of the mean of 3 to 5 uninfected animals. (D) Numbers of human CD3+ and CD4+ T cells in peripheral blood, (E) numbers of human CD3+ in LNs and spleen, and (F) percentages of TN, TCM, TEM, TEMRA in LNs and spleen of control, FTY-treated, and FTY+R7–treated mice. Bars in E and F represent mean + SD. CVT, cervico-vaginal tissue; cLNs, cervical LNs; aLNs, axillary LNs; mLNs, mesenteric LNs; TN, naive T cells; TCM, central memory T cells; TEM, effector memory T cells; TEMRA, effector memory T cells reexpressing CD45RA. Kruskal-Wallis test was used to perform statistical comparisons of mean percentages and viral load (#P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001), and Fisher exact test was used to perform statistical comparisons of the number of viremic and nonviremic tissues in treated versus untreated mice (*P < 0.05, **P < 0.01, ***P < 0.001).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts